Clinically approved multi-kinase inhibitors, such as nilotinib33,34 and antibody–drug conjugates35 strongly reduced DDR1-mediated CRC cell invasion and metastasis in mouse models, suggesting that DDR1 might be a potential target for cancer treatments. This evidence concerns the gene DDR1 and colorectal carcinoma.